
    
      This study is a phase IIIB, randomized, open label, non-comparative controlled trial, and
      prospectively enrolling 150 females to assess the efficacy and safety of the Enoxaparin
      (Group A) and Unfractionated Heparin (Group B) for Gynecologic Oncology Patients In the
      Kingdom of Saudi Arabia who required surgery or admission for the prevention of VTE.

      Patients who meet the Inclusion Criteria and signed an informed consent will be randomly
      assigned to 1 of the 2 treatment groups (Group A or Group B). Subjects will be assigned
      consecutive study numbers according to a predetermined random code generated by the
      Biostatistician. The randomisation will be based on a 1:1 ratio.
    
  